The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs

2002 ◽  
Vol 63 (11) ◽  
pp. 963-971 ◽  
Author(s):  
William H. Crown ◽  
Stan Finkelstein ◽  
Ernst R. Berndt ◽  
Davina Ling ◽  
Amy W. Poret ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Utilization ◽  
Care Utilization ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Resistant Depression ◽  
The Impact

P.0105 Health care utilization in treatment-resistant depression: a Swedish population based cohort study

2021 ◽  
Vol 53 ◽  
pp. S77
Author(s):  
P. Brenner ◽  
A. Nygren ◽  
D. Hägg ◽  
M. Tiger ◽  
M. O'Hara ◽  
...  
Keyword(s):  
Health Care ◽  
Cohort Study ◽  
Health Care Utilization ◽  
Population Based ◽  
Care Utilization ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Swedish Population ◽  
Resistant Depression

scholarly journals PMH18 HEALTH CARE UTILIZATION IN PATIENTS WITH TREATMENT RESISTANT DEPRESSION

2001 ◽  
Vol 4 (2) ◽  
pp. 146
Author(s):  
WH Crown ◽  
DCY Ling ◽  
SN Finkelstein ◽  
ER Berndt ◽  
AS White
Keyword(s):  
Health Care ◽  
Health Care Utilization ◽  
Care Utilization ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Resistant Depression

Targeting Treatment-Resistant Depression

2011 ◽  
Vol 24 (6) ◽  
pp. 520-533 ◽  
Author(s):  
Monica Mathys ◽  
Brian G. Mitchell
Keyword(s):  
Health Care ◽  
Care Utilization ◽  
Evidence Based ◽  
Efficacy And Safety ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Efficacious Treatment ◽  
Appropriate Therapy ◽  
Resistant Depression ◽  
Occupational Function

Only 50% of depressed patients achieve remission of symptoms after 2 trials of antidepressants. Therefore one half of patients are considered treatment resistant. Studies have shown that with each failed antidepressant, chances of remission continue to decline. Untreated depressive symptoms lead to impaired social and occupational function, decline of physical health, suicidal thoughts, and increased health care utilization. Clinicians recognize there is an urgent need to find an efficacious treatment, but it becomes more difficult to decide on an appropriate therapy once a patient has failed 2 to 3 trials of antidepressants. An evidence-based review was performed to assess the efficacy and safety of several different antidepressant strategies to help the clinician decide which may be beneficial for specific patients.

scholarly journals Role of the Pharmacist in Managing Treatment-Resistant Depression: A Focus on Ketamine

Pharmacy ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 118
Author(s):  
Linda Xing Yu Liu ◽  
Marina Golts ◽  
Virginia Fernandes
Keyword(s):  
Current Practice ◽  
Quality Care ◽  
Treatment Options ◽  
Critical Role ◽  
Transitions Of Care ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Resistant Depression ◽  
Multiple Treatments ◽  
The Impact

The impact of depression is well described in the literature, and it is most prominent in patients who have trialed multiple treatments. Treatment-resistant depression (TRD) is particularly debilitating, and it is associated with significant morbidity and mortality. Despite this, there seems to be therapeutic inertia in adopting novel therapies in current practice. Ketamine is an N-methyl-D-aspartate receptor antagonist and anesthetic agent which has recently been shown to be effective in the management of TRD when administered intravenously or intranasally. The treatments, however, are not easily accessible due to restrictions in prescribing and dispensing, high costs, and the slow uptake of evidence-based practice involving ketamine within the Canadian healthcare system. Given the limited treatment options for TRD, novel approaches should be considered and adopted into practice, and facilitated by a multi-disciplinary approach. Pharmacists play a critical role in ensuring access to quality care. This includes dissemination of evidence supporting pharmacological treatments and facilitating translation into current practice. Pharmacists are uniquely positioned to collaborate with prescribers and assess novel treatment options, such as ketamine, address modifiable barriers to treatment, and triage access to medications during transitions of care. Extending the reach of these novel psychiatric treatments in both tertiary and primary care settings creates an emerging role for pharmacists in the collaborative effort to better manage treatment-resistant depression.

The Impact of Behavioral Feeding Intervention on Health Care Utilization

2011 ◽  
Vol 40 (4) ◽  
pp. 282-296 ◽  
Author(s):  
Nancy F. Bandstra ◽  
William B. Crist ◽  
Anne Napier-Phillips ◽  
Gordon Flowerdew
Keyword(s):  
Health Care ◽  
Health Care Utilization ◽  
Care Utilization ◽  
The Impact

scholarly journals The impact of an mHealth monitoring system on health care utilization by mothers and children: an evaluation using routine health information in Rwanda

2018 ◽  
Vol 33 (8) ◽  
pp. 920-927 ◽  
Author(s):  
Hinda Ruton ◽  
Angele Musabyimana ◽  
Erick Gaju ◽  
Atakilt Berhe ◽  
Karen A Grépin ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Utilization ◽  
Health Information ◽  
Monitoring System ◽  
Care Utilization ◽  
Mothers And Children ◽  
The Impact

scholarly journals PRS14 THE IMPACT OF ASTHMA ON HEALTH CARE UTILIZATION AND EXPENDITURE OF PEDIATRIC PATIENTS

2010 ◽  
Vol 13 (3) ◽  
pp. A198
Author(s):  
X Song ◽  
R Shenolikar ◽  
LA Costa ◽  
J Anderson ◽  
BC Chu
Keyword(s):  
Health Care ◽  
Health Care Utilization ◽  
Pediatric Patients ◽  
Care Utilization ◽  
The Impact

scholarly journals Using Oral and Intranasal Dosage Forms of Ketamine for Managing Treatment-Resistant Depression: A Review of the Literature

2016 ◽  
Vol 4 (2) ◽  
pp. 64-71 ◽  
Author(s):  
Patrick Arthur Twohig ◽  
Vaughn Huckfeldt
Keyword(s):  
Health Care ◽  
Side Effects ◽  
Care Setting ◽  
Dosage Forms ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Similar Reduction ◽  
Aspartate Receptor ◽  
Pubmed Database ◽  
Resistant Depression

A lack of effective treatment for patients with treatment-resistant depression (TRD) has led to the evaluation of ketamine, an N-methyl- D-aspartate receptor antagonist. Despite the demonstrated short-term benefits of using intravenous (IV) ketamine, side effects and the difficulty in administering ketamine outside the health-care setting has raised interest in alternative dosage forms. Research articles evaluating oral or intranasal (IN) ketamine were retrieved from the PubMed database. Patients who received oral or IN ketamine experienced a similar reduction in depressive symptoms within 24 hours of treatment and fewer side effects compared to patients who received IV ketamine. Novel administration forms of ketamine provide an opportunity for patients with TRD to achieve remission with fewer adverse side effects. Future studies should continue to evaluate these administration strategies in the hope of promoting ketamine’s use outside health-care settings and for longer time periods.

scholarly journals The Impact of Provider Payments on Health Care Utilization: Evidence from Medicare and Medicaid

2021 ◽  
Author(s):  
Marika Cabral ◽  
Colleen Carey ◽  
Sarah Miller
Keyword(s):  
Health Care ◽  
Health Care Utilization ◽  
Care Utilization ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document